Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 5/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10397990 | 0.93 | KDM4E (0.79) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL11055348 | 0.87 | KDM4E (0.50) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL4076011 | 0.81 | IDO1 (0.49) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL10992179 | 0.79 | MAPK14 (0.83) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL11834419 | 0.79 | KDM4E (0.64) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL8011383 | 0.79 | KDM4E (0.64) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL12491361 | 0.79 | CYP3A4 (0.64) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL8119923 | 0.79 | KDM4E (0.64) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL224770 | 0.78 | KDM4E (1.00) | KDM4ECYP3A4MAPTIDO1MAPK14 | |
| SCHEMBL11853918 | 0.78 | KDM4E (0.49) | KDM4ECYP3A4MAPTIDO1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| US-4503065-A | ANTIARTHRITIC, ANALGESIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | KDM4E 1781/4885CYP3A4 2044/4885MAPT 599/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | KDM4E 1781/4885CYP3A4 2044/4885MAPT 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.